These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7622828)

  • 1. Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment?
    Gaebel W
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 5():11-6. PubMed ID: 7622828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent medication--an alternative?
    Gaebel W
    Acta Psychiatr Scand Suppl; 1994; 382():33-8. PubMed ID: 7916527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.
    Gaebel W; Jänner M; Frommann N; Pietzcker A; Köpcke W; Linden M; Müller P; Müller-Spahn F; Tegeler J
    Schizophr Res; 2002 Jan; 53(1-2):145-59. PubMed ID: 11728846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?
    Gaebel W; Frick U; Köpcke W; Linden M; Müller P; Müller-Spahn F; Pietzcker A; Tegeler J
    Br J Psychiatry Suppl; 1993 Sep; (21):8-12. PubMed ID: 8105814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Neuroleptic low-dose long-term strategy and intermittent therapy strategy in chronic schizophrenia--a critical review].
    Hofmann P; Melisch B; Zapotoczky HG; Kulhanek F
    Fortschr Neurol Psychiatr; 1993 Jun; 61(6):195-200. PubMed ID: 8101177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The routine use of atypical antipsychotic agents: maintenance treatment.
    Kinon BJ
    J Clin Psychiatry; 1998; 59 Suppl 19():18-22. PubMed ID: 9847048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
    Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
    BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years.
    Jolley AG; Hirsch SR; Morrison E; McRink A; Wilson L
    BMJ; 1990 Oct; 301(6756):837-42. PubMed ID: 2282421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.
    De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J
    CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early intervention, time-limited, targeted pharmacotherapy of schizophrenia.
    Carpenter WT; Heinrichs DW
    Schizophr Bull; 1983; 9(4):533-42. PubMed ID: 6140752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
    Shriqui CL
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of relapse in schizophrenia.
    Lieberman JA; Kane JM; Sarantakos S; Gadaleta D; Woerner M; Alvir J; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1987 Jul; 44(7):597-603. PubMed ID: 2886110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.
    Jolley AG; Hirsch SR; McRink A; Manchanda R
    BMJ; 1989 Apr; 298(6679):985-90. PubMed ID: 2567190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The early course of schizophrenia and long-term maintenance neuroleptic therapy.
    Nuechterlein KH; Gitlin MJ; Subotnik KL
    Arch Gen Psychiatry; 1995 Mar; 52(3):203-5. PubMed ID: 7872846
    [No Abstract]   [Full Text] [Related]  

  • 18. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.
    van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS
    Am J Psychiatry; 1998 Apr; 155(4):565-7. PubMed ID: 9546009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine in the long-term treatment of schizophrenia.
    Kane J
    Br J Psychiatry Suppl; 1999; (37):26-9. PubMed ID: 10211138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent vs maintenance medication in schizophrenia. Two-year results.
    Herz MI; Glazer WM; Mostert MA; Sheard MA; Szymanski HV; Hafez H; Mirza M; Vana J
    Arch Gen Psychiatry; 1991 Apr; 48(4):333-9. PubMed ID: 1672588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.